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Abstract
An association between genetic variants in the vitamin D receptor (VDR) gene and 
epithelial ovarian cancer (EOC) was previously reported in women of African ances-
try (AA). We sought to examine associations between genetic variants in VDR and 
additional genes from vitamin D biosynthesis and pathway targets (EGFR, UGT1A, 
UGT2A1/2, UGT2B, CYP3A4/5, CYP2R1, CYP27B1, CYP24A1, CYP11A1, and GC). 
Genotyping was performed using the custom‐designed 533,631 SNP Illumina 
OncoArray with imputation to the 1,000 Genomes Phase 3 v5 reference set in 755 
EOC cases, including 537 high‐grade serous (HGSOC), and 1,235 controls. All sub-
jects are of African ancestry (AA). Logistic regression was performed to estimate odds 
ratios (OR) and 95% confidence intervals (CI). We further evaluated statistical signifi-
cance of selected SNPs using the Bayesian False Discovery Probability (BFDP). A 
significant association with EOC was identified in the UGT2A1/2 region for the SNP 
rs10017134 (per allele OR = 1.4, 95% CI = 1.2‐1.7, P = 1.2 × 10−6, BFDP = 0.02); 
and an association with HGSOC was identified in the EGFR region for the SNP 
rs114972508 (per allele OR = 2.3, 95% CI = 1.6‐3.4, P = 1.6 × 10−5, BFDP = 0.29) 
and in the UGT2A1/2 region again for rs1017134 (per allele OR = 1.4, 95% 
CI = 1.2‐1.7, P = 2.3 × 10−5, BFDP = 0.23). Genetic variants in the EGFR and 
UGT2A1/2 may increase susceptibility of EOC in AA women. Future studies to vali-
date these findings are warranted. Alterations in EGFR and UGT2A1/2 could perturb 
enzyme efficacy, proliferation in ovaries, impact and mark susceptibility to EOC.
K E Y W O R D S
African ancestry risk, genetic association, ovarian cancer, vitamin D pathway
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1 |  INTRODUCTION
Women of African ancestry (AA) have the lowest incidence 
of ovarian cancer worldwide, but they tend to present with 
more advanced tumors and have lower 5‐year survival (35%) 
compared to women of European descent (47%) in nearly 
every cancer subtype.1,2 Compared to Caucasian women, 
there have been fewer published studies investigating the as-
sociation between common risk factors, such as tubal ligation, 
use of hormonal contraceptives, obesity, body powder and di-
etary patterns, and ovarian cancer risk in AA.1,3-9 Moreover, 
the investigation of genetic susceptibility to epithelial ovar-
ian cancer (EOC) in AA has not been comprehensive. The 
limited assessment of genetic susceptibility among AA is in 
modest sized study populations of candidate genes including 
the repeat polymorphisms of the androgen receptor (AR), vi-
tamin D receptor (VDR) and cellular transport genes, where 
an association with risk of ovarian cancer was observed.10-12
The vitamin D receptor mediates the regulation of a ple-
otropic cascade of physiological responses; including those 
involved in phase I and phase II detoxification and the epi-
dermal growth factor receptor (EGFR) proliferation path-
ways in ovarian and other cancer cell lines; through VDR/
DNA interactions and bioavailability of vitamin D.13-17 A 
VDR variant, rs7305032, was associated with ovarian can-
cer in 125 cases and 155 controls of AA but other observa-
tions were limited because of small sample size.11 Moreover, 
known genetic variations in the VDR/vitamin D biosynthesis 
and pathway target genes have been implicated in AA disease 
risk. Therefore an objective of this study was to assess those 
variants in ovarian cancer in women of African ancestry in a 
large sample.
Using a candidate gene approach, SNPs were selected 
from genes involved in vitamin D biosynthesis and metab-
olism; and putative targets of VDR regulation. Genes of 
the vitamin D biosynthesis pathways included cytochrome 
P450s:CYP2R1, CYP27B1, CYP24A1, CYP11A1, and group‐
specific component‐vitamin D‐binding protein (GC) which 
collectively are responsible for the homeostatic control and 
bioavailability of vitamin D.18-23 The candidate genes in-
volved in vitamin D metabolic processes included CYP3A4/5 
and UDP‐glucuronosyltransferase 1A (UGT1A) locus mem-
bers. They are responsible for glucuronidation and hydrox-
ylation of the biologically active and circulatory forms of 
vitamin D. These genes are also inclusive of candidates reg-
ulated by vitamin D/VDR binding and included CYP3A4/5, 
UGT1A locus members, EGFR and UDP‐glucuronosyltrans-
ferase 2 (UGT2) locus members; that are associated, in part, 
with other cancers in AA individuals.24-39 Thus, variants 
in VDR and additional genes from vitamin D biosynthesis 
and pathway targets are viable candidates to investigate the 
genetic underpinnings of ovarian cancer risk in women of 
African descent.
In this study, SNPs from 11 gene regions: VDR, EGFR, 
UGT1A, UGT2A1/2, UGT2B, CYP3A4/5, CYP2R1, 
CYP27B1, CYP24A1, CYP11A1, and GC, were genotyped, 
imputed then assessed for risk of EOC and high grade se-
rous ovarian cancer (HGSOC) in cases and controls of AA 
from the African American Cancer Epidemiology Study 
(AACES)40 and the Ovarian Cancer Association Consortium 
(OCAC).41
2 |  MATERIALS AND METHODS
2.1 | Study populations
The Genetic Associations and Mechanisms in Oncology 
(GAME‐ON) project comprised 63, mostly, case‐control stud-
ies from four continents (North America, Europe, Asia and 
Australia). Only 32 studies contributed subjects of African 
Ancestry, including AACES and studies in OCAC, and were 
included in the current analysis (Supplemental Table S1). 
AACES, previously described elsewhere,40 is a multi‐center 
population‐based case‐control study of newly diagnosed in-
vasive EOC in African American women that enrolled study 
subjects between 2010 and 2015. Established in 2005, OCAC 
is an international consortium focused on genetic association 
and pooled risk factor analyses. The current analyses in-
cluded 1990 samples: 1235 controls and 755 invasive EOC 
cases who passed quality control filters, all of whom were 
AA. The majority of the EOC cases were HGSOC (n = 537, 
71%), followed by 49 mucinous cases (7%), 28 endometri-
oid cases (4%), 23 clear cell cases (3%), 12 mixed histology 
(2%) and 53 other (7%). All subjects included in this analysis 
provided written informed consent as well as data and blood 
samples under ethically approved protocols.
2.2 | Genotyping, ancestry analysis and 
quality control
Genotyping of AA women from OCAC was completed 
using the custom‐designed 533,631 SNP array, the Illumina 
OncoArray. Sample level quality control included restriction 
to females, filter on call rate >95%, heterozygosity (either too 
big or too small), removal of ineligible samples, and relation-
ship inference to check for unexpected first degree relatives. 
SNP level quality control included filter on call rate >95%, 
and Hardy–Weinberg Equilibrium p‐value >1 × 10−5. After 
applying these procedures, 471,780 SNPs remained.
Intercontinental ancestry was calculated for the OCAC and 
AACES samples using the software package FastPop42 that 
was developed specifically for the OncoArray Consortium. 
Only the African ancestry samples defined as having 
>50% AA were used for the present analyses reported here. 
Seventy‐seven cases and 120 controls were omitted due to 
African ancestry <50% and one gender mismatch. Principal 
2508 |   GRANT eT Al.
components computed using FastPop were further used to ad-
just for population structure in our analyses.
2.3 | Genotype imputation analysis
Using the genotyped SNPs that passed quality control, hap-
lotypes were phased using SHAPEIT v2 followed by impu-
tation to the 1,000 Genomes Phase 3 v5 reference set using 
Minimac3.
2.4 | Gene region and SNP selection
Eleven gene regions were defined based on human genome 
build 37. SNPs within the selected regions were filtered on im-
putation quality score (minimac imputation R‐squared) >0.5 
for imputed SNPs, or Hardy–Weinberg Equilibrium p‐value 
>1.0 × 10−5 for genotyped SNPs. Quantile‐quantile plots 
on the EOC and HGSOC dataset (Manichaikul et al, unpub-
lished) have lambdas of 1.01 each within normal range.43 The 
imputation quality scores for significant SNPs are provided. 
We further applied filters on effective heterozygosity count 
(HC) > 30. After applying filters, the following number of 
SNPs remaining in each of the selected gene regions for EOC 
was: 288 in VDR, 433 in UGT2A1/2, 6302 in UGT2B, 919 in 
UGT1A, 963 in EGFR, 17 in CYP2R1, 4 in CYP27B1, 113 
in CYP24A1, 90 in CYP11A1, 411 in CYP3A4/5 and 296 in 
GC. For selected regions for HGSOC analysis, the number of 
SNPs was: 234 in VDR, 413 in UGT2A1/2, 5674 in UGT2B, 
833 in UGT1A, 824 in EGFR, 15 in CYP2R1, 4 in CYP27B1, 
106 in CYP24A1, 82 in CYP11A1, 375 in CYP3A4/5 and 282 
in GC.
2.5 | Statistical analysis
Genetic association testing was carried out with adjustment 
for two principal components (PCs) of ancestry using a logis-
tic regression model that accounts for genotype uncertainty 
under a score test as implemented in SNPTEST v2.5.2 to es-
timate odds ratios (OR) and 95% confidence intervals (CI). 
For each gene region, we applied a gene‐specific Bonferroni‐
threshold for statistical significance defined as 0.05/number 
of SNPs examined for that gene. We further assessed the 
main results with an alternative to the Bonferroni thresh-
old using the Bayesian False Discovery Probability (BFDP) 
which provides the posterior probability of a false discovery 
based on a given prior probability of nonnull association at a 
given SNP.44 For this study we specified a prior probability 
of association at each SNP under investigation based on the 
total number of SNPs within each candidate gene region as 
0.5 × 1/(NSNP/3) where NSNP represents the number of SNPs 
in the given candidate gene region. We considered NSNP/3 
to be an approximation of the effective number of independ-
ent SNPs within in each gene region, taking into account 
the fact that many SNPs will be correlated due to linkage 
disequilibrium. Accordingly, the specified prior indicates a 
50% chance of true discovery within each gene region, with 
the prior probability of nonnull association distributed ran-
domly among all SNPs within the region. In order to avoid 
spurious positive associations, we applied a filter on effective 
(HC) > 30 in each of cases and controls. Here, HC is de-
fined as N × MAF ×  (1‐MAF) for each SNP, N represents 
the sample size (either the number of cases or the number 
of controls), and MAF represents the SNP minor allele fre-
quency. Based on 755 EOC cases and 537 HGSOC cases, 
respectively, applying this filter equates to applying a SNP 
MAF filter of 4.2% and 6% in analysis of EOC and HGSOC, 
respectively. Statistical power calculations for AA study 
participants and Caucasians are included in Supplemental 
Tables S2 and S3.
3 |  RESULTS
3.1 | VDR pathway gene regions and risk of 
EOC
SNPs from 11 gene regions (CYP3A4/5,CYP2R1, CYP27B1, 
CYP24A1, CYP11A1, EGFR, GC, UGT1A, UGT2A1/2, 
UGT2B and VDR) from VDR biosynthesis and pathway 
T A B L E  1  Top SNP P‐values from gene regions associated with EOC in African American OncoArray analysis
SNP ID (Effect/other 
allele) Nearest gene(s)
Effect Allele 
Frequency N OR 95% CI P‐value
Bayesian False Discovery 
Probability (BFDP) Imputation quality
rs10017134 (C/T) 
UGT2A1/2a,b
0.73 1990 1.4 1.2‐1.7 1.2 × 10−6 0.020 0.998
rs2288741 (T/G) 
UGT2A1/2b
0.73 1990 1.4 1.2‐1.6 1.9 × 10−6 — —
rs11939884 (T/G) 
UGT2A1/2a,b
0.14 1990 0.7 0.5‐0.8 1.7 × 10−6 — —
aImputed. 
bBonferroni correction was applied to adjust for multiple SNPs comparisons. There were 433 SNPs in UGT2A1/2 gene. BFDP is reported based on a prior probability of 
association (pi0) equal to 0.6 * 1/(Number of SNPs/3). 
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targets were assessed for association with EOC (Supplemental 
Table S4). The top associations are reported in Table 1. 
Individuals carrying the major allele of SNP rs10017134 of 
the UGT2A1/2 gene region had an increased odds of EOC 
when corrected for multiple comparisons (OR = 1.4, 95% 
CI = 1.2‐1.7, P = 1.2 × 10−6). The BFDP for rs10017134 
of 0.020 corresponds to 98% posterior probability of non-
null association for this SNP. Significant associations with 
EOC were also observed for UGT2A1/2 SNPs, rs2288741 
and rs11939884. The variants are found in both UGT2A1 and 
UGT2A2 as the genes share common exons 2 through 6.45 
Supplemental Table S5 summarizes other notable (P < 0.01) 
SNP associations with EOC in the OncoArray analysis.
3.2 | VDR pathway gene regions and 
risk of HGSOC
SNPs from the 10 gene regions from VDR biosynthesis and 
pathway targets were assessed for association with HGSOC 
(Supplemental Table S4). The top associations are in reported 
in Table 2. Individuals carrying the minor allele of EGFR 
SNP rs114972508 had more than twofold increased odds of 
HGSOC (OR = 2.3, 95% CI = 1.2‐3.4, P = 1.6 × 10−5) (Table 
2). The posterior BFDP is 29% for SNP rs114972508 corre-
sponds to 71% posterior probability of nonnull association. 
SNP rs10017134 of the UGT2A1/2 gene region also showed 
association with HGSOC (OR = 1.4, 95% CI = 1.2‐1.7, 
P = 2.3 × 10−5) (Table 2). The posterior BFDP is 22.8%. 
Supplemental Table S6 summarizes other notable (P < 0.01) 
SNP associations with HGSOC in the OncoArray analysis.
4 |  DISCUSSION
Few studies have investigated the genetic susceptibility for 
ovarian cancer among women of African descent. The as-
sessment of candidate SNPs from chromosomal regions that 
contain genes regulated by VDR activity provides some evi-
dence of association with EOC risk. The notable findings from 
this analysis show, for the first time, that risk assessments of 
variants in the UGT2A1/2 and EGFR gene regions are sug-
gestive of associations with EOC and HGSOC. The results 
also demonstrate evidence of associations for other SNPs 
from the candidate gene regions with EOC and HGSOC. 
Although the candidate SNPs are located in intronic regions 
there is ample evidence that many gene regulatory regions 
are present in those regions including encoded microRNAs, 
alternate splice sites, and cis‐regulatory modules and tran-
scription factors binding sites.46-48 In addition, recent studies 
have shown using targeted RNAseq analysis that there are 
numerous splice variants of the UGT genes.49
The UGT2A1 and 2A2 genes are distinguished by unique 
first exons joined to common exons 2‐6 and are located 
downstream of UGT2B4 on chromosome 4.45 UGT2A tran-
scripts have been detected in several extrahepatic tissues such 
as the lung, trachea, larynx, intestine, pancreas, and kidney.50 
UGT2A1 is an extrahepatic enzyme that is expressed mainly 
in the nasal epithelium, catalyzing the glucuronidation of tes-
tosterone and epitestosterone at considerable rates and has 
similar kinetics as the UGT2B gene family members.51 There 
are reports that this enzyme also has activity toward estrogen 
metabolites epiestradiol and β‐estradiol.52 UGT2A1 has ex-
hibited highest expression in the lung, followed by trachea, 
tonsil, larynx, colon, olfactory.53 UGT2A2 mRNA expres-
sion was reported in fetal and adult nasal mucosa tissues.54 
However, unlike UGT2A1, other expression analyses sug-
gested that wild‐type UGT2A2 had the highest expression in 
the breast, followed by trachea, larynx, and kidney.55
Neither the UGT2A1 gene, nor UGT2A2 expression have 
been examined in ovarian tissue. However, VDR ChIPseq 
peak locations have been identified 430 kb downstream of 
the UGT2A1/2 locus in experiments with THP‐1 cells treated 
with 1a,25(OH)2D3, the biologically active form of the vi-
tamin D hormone, suggestive of a regulatory role for vita-
min D.56 Splice variants found in UGT2A1/2 that are highly 
conserved among both UGT1A and UGT2 gene families 
have been implicated in altered glucuronidation activity 
against tobacco carcinogenesis.49,53,55,57 Two of the UGT2A1 
SNPs associated with EOC and HGSOC in this study are 
intron variants (rs10017134 and rs2288741) while the third 
T A B L E  2  Top SNP P‐values from gene regions associated with HGSOC in African American OncoArray analysis
SNP ID (Effect/other allele) 
Nearest gene(s)
Effect Allele 
Frequency N OR 95% CI P‐value
Bayesian False Discovery 
Probability (BFDP) Imputation quality
rs114972508 (T/C) EGFRa,b 0.04 1772 2.3 1.2‐3.4 1.6 × 10−5 0.293 0.890
rs10017134 (C/T) 
UGT2A1/2a,b
0.72 1772 1.4 1.2‐1.7 2.3 × 10−5 0.228 0.998
rs2288741 (T/G) 
UGT2A1/2b
0.72 1772 1.4 1.2‐1.7 3.1 × 10−5 — —
aImputed. 
bBonferroni correction was applied to adjust for multiple SNPs comparisons. There were 824 SNPs in EGFR gene, and 413 SNPs in UGT2A1/2 gene. BFDP is reported 
based on a prior probability of association (pi0) equal to 0.5 * 1/(Number of SNPs/3). 
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(rs11939884) is a 3’ UTR variant. It is probable that these 
variants alter enzyme function in target tissues including 
ovarian and/or alter risk in AA smokers. Of note, cigarette 
smoking has been found to be associated with the risk of mu-
cinous EOC, but not HGSOC among Caucasian women.58 
Moreover, providing some plausibility for the mechanism of 
the observed SNP association, a recent report suggests that 
cigarette smoking may be associated with serous EOC among 
African American women although a dose‐response relation-
ship was not observed.59 The association of genes from the 
UGT superfamily with ovarian cancer in AA is consistent 
with significant associations observed for Caucasian women 
for UGT1A.12 However in this study, no association was ob-
served for AA samples with SNPs with a MAF of 0.42 for the 
risk allele while associations were observed in Caucasians 
with SNPs with a MAF of 0.07. Some but not all MAFs for 
the relationships observed in this study differ by race so it is 
unlikely to explain racial differences in risk.
The EGFR gene product has been a chemotherapeu-
tic target for EOC since overexpression has been linked to 
poor prognosis in ovarian cancer patients.60-62 The signaling 
pathway for EGFR is mediated by ligands including the epi-
dermal growth factor in the regulation of cell proliferation, 
differentiation and apoptosis in normal cells. Research into 
the mechanisms of EGFR overexpression has focused on mu-
tations and amplifications in the coding region of the gene 
containing the receptor tyrosine kinase domain.63 However, 
few studies on SNP variants in this region have been linked to 
EOC or other ovarian cancer histologic subtypes.61,63 EGFR 
SNP rs114972508 is located in intron 1 of the EGFR gene. 
The location of the SNP is approximately 70 kb upstream of 
a VDR binding site also within EGFR intron 1 that has been 
shown experimentally to down regulate EGFR expression 
and proliferative function.15 Perhaps changes in the intron 
sequences may impact EGFR function and subsequently be 
as critical to cellular homeostasis as the receptor tyrosine 
function that has been extensively researched. Thus, EGFR 
SNPs could be abrogating vitamin D hormone regulation of 
ovarian cell proliferation and increasing susceptibility for the 
development of HGSOC in AA women.
Although we were unable to confirm the association be-
tween previously identified VDR variants and risk of EOC, 
a recent case‐control study of women of European ancestry 
(10,065 cases, 21,654 controls) showed that SNPs associ-
ated with decreased circulating 25‐hydroxyvitamin D were 
associated with ovarian cancer and HGSOC64 while another 
study showed that AA women exposed to increased sunlight 
had a decreased risk for ovarian cancer.8 These observations 
suggest that other mechanisms affecting vitamin D hormone 
activity independent of the VDR may be important in ovarian 
cancer etiology.
The main observations in the current study result 
from associations of imputations of genotyped SNPs but 
independent of VDR variant association with EOC and 
HGSOC. The VDR SNPs previously observed to be asso-
ciated with the risk of EOC,11 including rs7975232 and 
rs7305032, were not associated with risk of EOC in the cur-
rent study (Supplemental Table S7). A look up of the sig-
nificant study SNPs in archived OCAC data on Caucacians 
shows no significant associations for the UGT2A1/2 SNPs. 
Data on the EGFR SNP were not available (Supplemental 
Table S8). Other VDR SNPs showed nominal (nonBonfer-
roni corrected) associations with EOC but not with HGSOC 
(Supplemental Table S7). Although the largest study to 
date of genetic association with EOC in AA, the modest 
sample size remains a limitation of the current study and 
therefore some of the nominal SNP associations may be a 
result of inadequate power. The analyses are underpowered 
for discovery analysis across the selected gene regions and 
important associations may have been missed, nonetheless, 
we still found significantly associations with EOC and 
HGSOC. Several suggestive and nominal SNP associations 
(outside of Bonferroni significance) may provide some in-
sight and consideration for future experimental studies to 
further explore the relevance of vitamin D biosynthesis and 
pathway target genes. Larger studies of AA are warranted 
to clarify these finding.
In summary, this study reports, for the first time, an asso-
ciation between EGFR and UGT2A1/2 variants with ovarian 
cancer risk in AA women. These gene variants could perturb 
cell proliferation and enzyme efficacy in ovaries and impact 
susceptibility to ovarian cancer by altering growth and inter-
cellular hormone metabolism. Future studies are needed to 
validate the associations of the imputed SNPs and to deter-
mine their impact on cancer development. Currently, there 
are no published reports of population studies of UGT2A1/2 
polymorphisms in Europeans or other racially distinct groups 
in larger sample sizes than this AA study that would allow 
intricate gene‐environment analysis. At this present time, 
there is only limited evidence that UGT2B gene region vari-
ants may be associated with differences in nicotine metabo-
lism across African American, Native Hawaiian, Caucasian, 
Latino, and Japanese American smokers.65,66 Analyses of the 
UGT2A1/2 variants across populations may reveal differen-
tial risk to ovarian disease. In addition, expression and func-
tional analysis in ovarian tissue needs to be accomplished to 
elucidate the impact on tissue homeostasis. In spite of the 
limitations of this study, these results provide new insight 
into proliferative and hormone target pathways that may rep-
resent important opportunities for the development of che-
motherapeutic targets and intervention strategies.
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